Compounders Research Compare

Estrella Immunopharma, Inc.(ESLA)

Biotechnology · EmeryVille, CA

$0.45+0.01 (+2.25%)

Delayed quote: Oct 6, 2026, 11:20 AM EDT

About Estrella Immunopharma, Inc.

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.

EmeryVille, CA

3 employees

www.estrellabio.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Cheng Liu

View full financials

EV/EBITDA Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/EBITDA ratio is N/A as of 2026-10-06T15:26:48.628Z.

Stored calculation inputs

Calculation as of: 2026-10-06T15:26:48.628Z.

Quote observation: 2026-10-06T15:20:47.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 19,195,086
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 146,670
TTM operating EBITDA · period ending 2026-06-30: -9,790,659

FMP input reference: 2d15fccd73dd71321fa30efb235d10704747171fee005d1a5dd6499fafc6c703

EV/Sales|P/E Ratio|EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

ESLA EV/EBITDA Ratio Metrics

EV/EBITDA RATIO

N/A

ESLA Competitors' EV/EBITDA Ratio

Estrella Immunopharma, Inc.

Current

Market Cap

$19.20M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

P3 Health Partners Inc.

Market Cap

$19.72M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Actuate Therapeutics Inc

Market Cap

$19.86M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Modular Medical, Inc.

Market Cap

$21.03M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Neuphoria Therapeutics Inc.

Market Cap

$18.73M

EV/EBITDA Ratio

N/A

TTM Avg

466.09x

3Y Avg

466.09x

5Y Avg

466.09x

NextCure, Inc.

Market Cap

$18.67M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Aytu BioPharma, Inc.

Market Cap

$22.22M

EV/EBITDA Ratio

N/A

TTM Avg

6.88x

3Y Avg

5.95x

5Y Avg

5.95x

LeonaBio, Inc.

Market Cap

$21.93M

EV/EBITDA Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Cosmos Health Inc.

Market Cap

$17.28M

EV/EBITDA Ratio

N/A

TTM Avg

47.55x

3Y Avg

64.91x

5Y Avg

64.91x

Lipocine Inc.

Market Cap

$17.19M

EV/EBITDA Ratio

N/A

TTM Avg

19.19x

3Y Avg

19.19x

5Y Avg

19.19x

NAME	MARKET CAP	EV/EBITDA RATIO	TTM	3Y	5Y
Estrella Immunopharma, Inc. (ESLA)	$19.20M	N/A	N/A	N/A	N/A
P3 Health Partners Inc. (PIII)vs ›	$19.72M	N/A	N/A	N/A	N/A
Actuate Therapeutics Inc (ACTU)vs ›	$19.86M	N/A	N/A	N/A	N/A
Modular Medical, Inc. (MODD)vs ›	$21.03M	N/A	N/A	N/A	N/A
Neuphoria Therapeutics Inc. (NEUP)vs ›	$18.73M	N/A	466.09x	466.09x	466.09x
NextCure, Inc. (NXTC)vs ›	$18.67M	N/A	N/A	N/A	N/A
Aytu BioPharma, Inc. (AYTU)vs ›	$22.22M	N/A	6.88x	5.95x	5.95x
LeonaBio, Inc. (LONA)vs ›	$21.93M	N/A	N/A	N/A	N/A
Cosmos Health Inc. (COSM)vs ›	$17.28M	N/A	47.55x	64.91x	64.91x
Lipocine Inc. (LPCN)vs ›	$17.19M	N/A	19.19x	19.19x	19.19x

EV/EBITDA Ratio Formula & Definition

EV/EBITDA = Enterprise Value / EBITDA (TTM)

Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/Sales P/E Ratio EBITDA All Metrics